Is Vimta Labs a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Vimta Labs Ltd is a average quality company .

Is Vimta Labs undervalued or overvalued?

The key valuation ratios of Vimta Labs Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Vimta Labs share price return in the past 10 years?

Vimta Labs Ltd share price has appreciated 28.3% annually (CAGR) over the past ten years.

Is Vimta Labs a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Vimta Labs Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

Vimta Labs Ltd - Stock Valuation and Financial Performance

Name: Vimta Labs
Brand: Vimta Labs

BSE: 524394 | NSE: VIMTALABS | Pharmaceuticals & Drugs | Small Cap

Place order

Vimta Labs Share Price

₹926.55 17.50 1.93%
as on 03-Dec'24 16:59

10 Year X-Ray of Vimta Labs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	5.8%	7%	11.2%	16.6%	20.4%	6%	14.2%	23.9%	24.3%	17%	-
Value Creation Index ⓘ	-0.6	-0.5	-0.2	0.2	0.5	-0.6	0.0	0.7	0.7	0.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	107	125	154	183	213	181	209	276	315	313	322
Sales YoY Gr.	-	16.3%	23.4%	19.2%	15.9%	-15%	15.7%	32%	14.2%	-0.7%	-
Adj EPS ⓘ	2.2	2.9	5	7.5	11.3	2.6	9.8	19	21	17.3	22.2
YoY Gr.	-	31.5%	71.9%	51.9%	49.7%	-76.7%	272.1%	95%	10.4%	-17.7%	-
BVPS (₹) ⓘ	55.3	57	61.6	68.8	77.6	78.2	87.9	104.4	123.9	139.6	152.2
Adj Net Profit ⓘ	4.8	6.4	10.9	16.6	24.9	5.8	21.6	42	46.5	38.3	49
Cash Flow from Ops. ⓘ	15.3	-1	23.9	33.4	39.3	24.4	37	58.7	86.5	59.1	-
Debt/CF from Ops. ⓘ	0.2	-25.6	1.8	1.2	0.7	1.3	0.8	0.3	0.2	0.3	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	12.6%	8%	14.4%	-0.7%
Adj EPS ⓘ	25.8%	8.9%	21%	-17.7%
BVPSⓘ	10.8%	12.5%	16.7%	12.7%
Share Price	28.3%	58.1%	35.1%	122.6%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	4	5.1	8.3	11.5	15.4	3.4	11.7	19.6	18.1	12.8	15.2
Op. Profit Mgn % ⓘ	16.2	15.2	18.1	24.8	27.2	16.6	25.4	29	29.7	26.7	30.2
Net Profit Mgn % ⓘ	4.5	5.1	7.1	9.1	11.7	3.2	10.3	15.2	14.7	12.2	15.3
Debt to Equity ⓘ	0	0.2	0.3	0.3	0.2	0.2	0.2	0.1	0.1	0.1	0
Working Cap Days ⓘ	187	199	187	168	158	195	186	158	148	156	90
Cash Conv. Cycle ⓘ	112	118	99	92	101	128	113	95	92	107	54

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 14.39%

Net Profit is growing at healthy rate in last 3 years 20.99%

Return on Equity has declined versus last 3 years average to 15.20%

Sales growth is not so good in last 4 quarters at 7.09%

Latest Financials - Vimta Labs Ltd.

	Standalone	Consolidated
TTM EPS (₹)	22.2	22.5
TTM Sales (₹ Cr.)	322	328
BVPS (₹.) ⓘ	152.2	154.3
Reserves (₹ Cr.) ⓘ	334	338
P/BV ⓘ	5.97	5.89
PE ⓘ	41.00	40.38

From the Market
52 Week Low / High (₹)	390.60 / 932.75
All Time Low / High (₹)	0.20 / 932.75
Market Cap (₹ Cr.)	2,019
Equity (₹ Cr.)	4.4
Face Value (₹)	2
Industry PE ⓘ	44.7

Management X-Ray of Vimta Labs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Vimta Labs

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Vimta Labs

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	107	125	154	183	213	181	209	276	315	313
Operating Expenses ⓘ	90	106	127	138	155	151	156	196	222	229
Manufacturing Costs	46	53	59	59	68	63	68	90	87	90
Material Costs	-3	0	0	2	-1	0	3	0	0	0
Employee Cost	29	33	43	49	55	58	57	71	86	95
Other Costs ⓘ	18	19	24	28	33	29	28	36	49	45
Operating Profit ⓘ	17	19	27	45	58	30	53	80	94	84
Operating Profit Margin (%)	16.2%	15.1%	17.8%	24.7%	27.1%	16.6%	25.2%	28.9%	29.7%	26.7%
Other Income ⓘ	1	1	1	1	2	3	1	1	3	4
Interest ⓘ	1	1	2	5	5	4	2	1	3	2
Depreciation ⓘ	11	10	10	16	20	21	23	23	31	34
Exceptional Items ⓘ	0	0	0	0	0	0	0	-1	0	0
Profit Before Tax ⓘ	7	8	17	26	35	8	28	55	64	52
Tax ⓘ	2	2	6	9	10	1	7	14	17	13
Profit After Tax	5	6	11	16	25	7	21	41	47	39
PAT Margin (%)	4.7%	5.2%	6.9%	9.0%	11.9%	3.8%	10.2%	14.9%	15.0%	12.4%
Adjusted EPS (₹)	2.3	2.9	4.8	7.4	11.5	3.1	9.6	18.6	21.4	17.5
Dividend Payout Ratio (%)	44%	34%	0%	27%	17%	0%	21%	11%	9%	11%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	122	126	136	152	172	173	194	231	274	310
Share Capital ⓘ	4	4	4	4	4	4	4	4	4	4
Reserves ⓘ	118	122	132	148	167	169	190	226	270	305
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	4	26	37	33	17	22	22	13	10	14
Long Term Debt	0	16	18	19	12	5	14	13	10	9
Short Term Debt	4	10	19	13	5	18	8	0	0	5
Trade Payables	7	6	15	13	11	10	15	12	14	8
Others Liabilities ⓘ	14	18	33	35	38	39	41	49	58	56
Total Liabilities ⓘ	146	176	222	232	237	244	272	304	356	388
Fixed Assets
Gross Block	222	231	98	166	180	197	216	266	300	328
Accumulated Depreciation	134	143	10	25	45	66	88	105	133	165
Net Fixed Assetsⓘ	88	88	88	140	135	131	128	162	168	163
CWIP ⓘ	0	6	53	0	4	2	17	0	12	59
Investmentsⓘ	0	0	0	0	0	6	6	6	6	6
Inventories	16	16	15	18	19	17	15	17	23	25
Trade Receivables	26	38	42	56	59	58	73	77	80	86
Cash Equivalents	1	3	1	3	3	7	7	11	39	24
Others Assetsⓘ	15	25	22	15	18	24	26	30	28	25
Total Assets ⓘ	146	176	222	232	237	244	272	304	356	388

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	15	-1	24	33	39	24	37	59	87	59
PBT ⓘ	7	8	17	26	35	8	28	55	64	52
Adjustment ⓘ	12	11	12	23	30	23	29	31	39	37
Changes in Working Capital ⓘ	-1	-19	1	-9	-16	-1	-13	-11	-4	-15
Tax Paid ⓘ	-1	-2	-5	-6	-10	-6	-7	-17	-12	-15
Cash Flow From Investing Activity ⓘ	-8	-16	-39	-24	-16	-20	-32	-38	-57	-75
Capex	-8	-16	-40	-24	-16	-14	-32	-39	-50	-73
Net Investments	0	0	0	0	0	0	1	0	-9	-3
Others ⓘ	0	0	0	1	1	-6	0	1	1	2
Cash Flow From Financing Activityⓘ	-9	19	13	-8	-23	-1	-5	-16	-11	-2
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	16	8	2	-7	-6	7	-3	-5	-1
Interest Paid ⓘ	0	-1	-2	-4	-3	-2	-2	-1	-1	-1
Dividend Paid ⓘ	-4	-2	-3	0	-5	-5	0	-4	-4	-4
Others ⓘ	-4	6	9	-6	-8	12	-9	-8	0	5
Net Cash Flow ⓘ	-1	2	-2	1	1	3	1	5	19	-17

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	4.17	5.18	8.08	11.4	15.64	4.02	11.58	19.32	18.73	13.29
ROCE (%)	5.82	6.95	11.22	16.55	20.42	6.01	14.24	23.85	24.25	17
Asset Turnover Ratio	0.73	0.77	0.77	0.81	0.91	0.75	0.81	0.96	0.95	0.84
PAT to CFO Conversion(x)	3	-0.17	2.18	2.06	1.56	3.43	1.76	1.44	1.85	1.51
Working Capital Days
Receivable Days	92	93	95	98	98	117	114	99	91	97
Inventory Days	45	46	37	33	32	37	28	21	23	28
Payable Days	-778	0	0	2,187	-5,631	0	1,517	0	0	0

Vimta Labs Ltd Stock News

Vimta Labs Ltd FAQs

What is the share price of Vimta Labs?

Company share prices are keep on changing according to the market conditions. The closing price of Vimta Labs on 03-Dec-2024 16:59 is ₹926.5.

What is the market cap of Vimta Labs?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Dec-2024 16:59 the market cap of Vimta Labs stood at ₹2,019.3.

What is the P/E ratio of Vimta Labs?

The latest P/E ratio of Vimta Labs as of 03-Dec-2024 16:59 is 41.00.

What is the P/B ratio of Vimta Labs?

The latest P/B ratio of Vimta Labs as of 03-Dec-2024 16:59 is 5.97.

What is the 52-week high and low of Vimta Labs?

The 52-week high of Vimta Labs is ₹932.8 and the 52-week low is ₹390.6.

What is the TTM revenue of Vimta Labs?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Vimta Labs is ₹321.8 ( Cr.) .

About Vimta Labs Ltd

Vimta Labs is Indiaâ€™s leading contract research and testing organization. Established in 1984, Vimta has an envious track record of serving several market leaders across the globe.

Vimta supports regulatory authorities in mandatory certification of food and agri products exported from India. Vimta assists the food industry commissions for nutritional labelling, food safety evaluations, trace analysis and shelf life studies.

Vimta has a team of 684 professionals comprising 446 scientists in various disciplines such as chemistry, pharma, medicine, microbiology, molecular biology and informatics. The team is slated to double in next three years.

Vimta is a multi-site organization with more than 300,000 sqft world class laboratory facilities. The technologies deployed at Vimta are current and leading edge, duly validated.

Vimta has over 12 years of experience in providing preclinical services to Pharma companies world-wide accordance with the guidelines prescribed by international agencies.

Vimta has a state-of-art building of Class 10,000 Pre-clinical facility with a total built up area of 33,000 sq.ft. with 32 rodent experimental rooms, 5 procedure rooms, separate quarantine facility and distinct non-rodent facility with 48 SS kennels with a comfortable perch, liberal exercise area.

It provides services in pharmacology, toxicology and DMPK areas. The toxicology services include but not limited to in-vivo and in-vitro genotoxicity, acute to chronic toxicity, carcinogenicity, reproductive toxicity studies, safety pharmacology, and immunotoxicology. Pharmacology services are available in various therapeutics areas such as pain & inflammation, metabolic disorders, respiratory, CNS, and xenograft & allograft models for oncology. In addition to the regulatory studies we use tailor-made in vitro and in vivo ADME techniques to help profile your drug candidate in both rodent and non-rodent animals models.

Services offered by the company: